{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:49:31Z","timestamp":1784573371830,"version":"3.55.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The development of immune-related adverse events (irAEs) has been associated with improved survival outcomes in non-small cell lung cancer (NSCLC). However, this association\u2019s extent across race and ethnicity remains uncertain. We evaluated the association between the development of irAEs and treatment outcomes across racially diverse groups treated at a safety net hospital.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective chart review was performed to identify patients with advanced NSCLC treated between 2015 and 2020. The incidence of irAEs across racial subgroups was compared using logistic regression analysis. Cox regression analysis was performed to evaluate the association between the development of irAEs and treatment outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 138 NSCLC patients treated with immune checkpoint inhibitors (ICIs), of whom 50% identified as non-Hispanic Black (NHB). Incidence of irAEs was 28%, with no significant difference between NHB and other racial groups. However, females [OR 2.3, 95% CI, (1.1-4.8)] and patients with Medicaid or MassHealth insurance had a higher incidence of irAEs [OR 2.7 (1.2-5.7)]. Additionally, patients with irAEs had a lower risk of disease progression (multivariable HR 0.46, 95% CI, 0.23-0.92) compared to those without irAEs. The association between irAEs and improved progression free survival (PFS) in NHB patients was similar to the other racial group [median PFS 246 vs 181 days; HR 0.87 (0.58-1.29)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We demonstrated a similar incidence of irAEs in NHB patients with NSCLC as compared to other racial groups. Patients who developed irAEs experienced significantly improved survival outcomes. This association remained independent of race and ethnicity, underscoring the importance of providing unbiased treatment recommendations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae279","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:06:53Z","timestamp":1732752413000},"source":"Crossref","is-referenced-by-count":6,"title":["The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-2068","authenticated-orcid":false,"given":"Amr","family":"Radwan","sequence":"first","affiliation":[{"name":"Section of Hematology and Medical Oncology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine , MA\u00a002118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9899-6333","authenticated-orcid":false,"given":"Chinmay T","family":"Jani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center , Miami, FL\u00a033166 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Al Omari","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care, Temple University , Philadelphia, PA 19140 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini","family":"Patel","sequence":"additional","affiliation":[{"name":"Boston University School of Public Health , Boston, MA 02118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Burns","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine , MA\u00a002118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Mackay","sequence":"additional","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center , MA 02215 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuping","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Graduate Medical Sciences, Boston University Chobanian and Avedisian School of Medicine , MA 02118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana","family":"Mahdaviani","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine , MA\u00a002118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle","family":"Davidson","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine , MA\u00a002118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health , Boston, MA 02118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"Everett","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine , MA\u00a002118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Suzuki","sequence":"additional","affiliation":[{"name":"INOVA, Department of Surgery, Division of Thoracic Surgery , Falls Church, VA 22042 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley S","family":"Mak","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine , Boston, MA 02118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H","family":"Kulke","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine , MA\u00a002118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-3004","authenticated-orcid":false,"given":"Umit","family":"Tapan","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine , MA\u00a002118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2025033007272381800_CIT0001","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1159\/000510385","article-title":"Immune modulation in lung cancer: current concepts and future strategies","volume":"99","author":"Gaissmaier","year":"2020","journal-title":"Respiration"},{"key":"2025033007272381800_CIT0002","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2025033007272381800_CIT0003","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2025033007272381800_CIT0004","doi-asserted-by":"publisher","first-page":"21","DOI":"10.17925\/EE.2021.17.1.21","article-title":"Organ-specific adverse events of immune checkpoint inhibitor therapy, with special reference to endocrinopathies","volume":"17","author":"George","year":"2021","journal-title":"touchREV Endocrinol"},{"key":"2025033007272381800_CIT0005","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025033007272381800_CIT0006","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.cllc.2020.06.010","article-title":"Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression &gt;\/= 50% and their relationship with clinical outcomes","volume":"21","author":"Cortellini","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2025033007272381800_CIT0007","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1634\/theoncologist.2012-0483","article-title":"Ipilimumab and its toxicities: a multidisciplinary approach","volume":"18","author":"Fecher","year":"2013","journal-title":"Oncologist"},{"key":"2025033007272381800_CIT0008","doi-asserted-by":"publisher","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2014a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2025033007272381800_CIT0009","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.bulcan.2020.04.019","article-title":"Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab","volume":"107","author":"Bouhlel","year":"2020","journal-title":"Bull Cancer"},{"key":"2025033007272381800_CIT0010","doi-asserted-by":"publisher","first-page":"703893","DOI":"10.3389\/fonc.2021.703893","article-title":"Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer","volume":"11","author":"Daniello","year":"2021","journal-title":"Front Oncol"},{"key":"2025033007272381800_CIT0011","doi-asserted-by":"publisher","first-page":"e889","DOI":"10.1016\/j.cllc.2021.05.004","article-title":"Effect of immune-related adverse events and pneumonitis on prognosis in advanced non-small cell lung cancer: a comprehensive systematic review and meta-analysis","volume":"22","author":"Li","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2025033007272381800_CIT0012","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025033007272381800_CIT0013","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025033007272381800_CIT0014","doi-asserted-by":"publisher","first-page":"pkaa060","DOI":"10.1093\/jncics\/pkaa060","article-title":"Racial and ethnic disparities among participants in US-Based phase 3 randomized cancer clinical trials","volume":"4","author":"Grant","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2025033007272381800_CIT0015","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5306\/wjco.v12.i2.103","article-title":"Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses","volume":"12","author":"Peravali","year":"2021","journal-title":"World J Clin Oncol"},{"key":"2025033007272381800_CIT0016","doi-asserted-by":"publisher","first-page":"e1226","DOI":"10.1002\/onco.13780","article-title":"Analysis of real-world data to investigate the impact of race and ethnicity on response to programmed cell death-1 and programmed cell death-ligand 1 inhibitors in advanced non-small cell lung cancers","volume":"26","author":"Ayers","year":"2021","journal-title":"Oncologist"},{"key":"2025033007272381800_CIT0017","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1002\/cncr.33141","article-title":"Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer","volume":"126","author":"Nazha","year":"2020","journal-title":"Cancer"},{"key":"2025033007272381800_CIT0018","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2025033007272381800_CIT0019","doi-asserted-by":"publisher","first-page":"e0227256","DOI":"10.1371\/journal.pone.0227256","article-title":"Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer","volume":"15","author":"Huang Bartlett","year":"2020","journal-title":"PLoS One"},{"key":"2025033007272381800_CIT0020","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s12325-021-01659-0","article-title":"Characterization of a real-world response variable and comparison with RECIST-based response rates from clinical trials in advanced NSCLC","volume":"38","author":"Ma","year":"2021","journal-title":"Adv Ther"},{"key":"2025033007272381800_CIT0021","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025033007272381800_CIT0022","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11096-022-01395-7","article-title":"Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system","volume":"44","author":"Chen","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"2025033007272381800_CIT0023","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025033007272381800_CIT0024","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","article-title":"Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC Patients","volume":"20","author":"Cortellini","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2025033007272381800_CIT0025","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer","volume":"19","author":"Owen","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2025033007272381800_CIT0026","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with Nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025033007272381800_CIT0027","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2025033007272381800_CIT0028","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/cncr.28617","article-title":"Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period","volume":"120","author":"Aizer","year":"2014","journal-title":"Cancer"},{"key":"2025033007272381800_CIT0029","first-page":"A2339","article-title":"Lung cancer mortality in the United States between 1999 and 2019: an observational analysis of disparities by gender and race","volume":"2022","author":"Jani","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025033007272381800_CIT0030","volume-title":"SEER Cancer Statistics Review, 1975-2013","author":"Howlader"},{"key":"2025033007272381800_CIT0031","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.sste.2009.07.007","article-title":"Racial disparities in lung cancer mortality in U.S. congressional districts, 1990-2001","volume":"1","author":"Gallagher","year":"2009","journal-title":"Spat Spatiotemporal Epidemiol"},{"key":"2025033007272381800_CIT0032","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7252","article-title":"Achieving equity in lung cancer screening for black individuals requires innovation to move beyond \u201cEqual\u201d Guidelines","volume":"8","author":"Robbins","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025033007272381800_CIT0033","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamasurg.2021.0242","article-title":"New USPSTF guidelines for lung cancer screening: better but not enough","volume":"156","author":"Colson","year":"2021","journal-title":"JAMA Surg"},{"key":"2025033007272381800_CIT0034","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/jnci\/djy206","article-title":"Racial\/ethnic differences in lung cancer incidence in the multiethnic cohort study: an update","volume":"111","author":"Stram","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025033007272381800_CIT0035","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/(sici)1097-0142(19970101)79:1&lt;45::aid-cncr7&gt;3.0.co;2-l","article-title":"Lung carcinoma in African Americans and whites. A population-based study in metropolitan Detroit, Michigan","volume":"79","author":"Schwartz","year":"1997","journal-title":"Cancer"},{"key":"2025033007272381800_CIT0036","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jnma.2017.09.003","article-title":"Racial disparities in lung cancer screening: an exploratory investigation","volume":"110","author":"Japuntich","year":"2018","journal-title":"J Natl Med Assoc"},{"key":"2025033007272381800_CIT0037","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.athoracsur.2021.04.096","article-title":"The impact of residential racial segregation on non-small cell lung cancer treatment and outcomes","volume":"113","author":"Annesi","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"2025033007272381800_CIT0038","doi-asserted-by":"publisher","first-page":"100109","DOI":"10.1016\/j.jtocrr.2020.100109","article-title":"Racial and other healthcare disparities in patients with extensive-stage SCLC","volume":"2","author":"Tapan","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"2025033007272381800_CIT0039","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jnci\/94.4.284","article-title":"Outcomes among African-American\/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B","volume":"94","author":"Blackstock","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2025033007272381800_CIT0040","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/cncr.24248","article-title":"Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer","volume":"115","author":"Hardy","year":"2009","journal-title":"Cancer"},{"key":"2025033007272381800_CIT0041","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1186\/2193-1801-3-710","article-title":"Race, insurance type, and stage of presentation among lung cancer patients","volume":"3","author":"Efird","year":"2014","journal-title":"Springerplus"},{"key":"2025033007272381800_CIT0042","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1470-2045(08)70032-9","article-title":"Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis","volume":"9","author":"Halpern","year":"2008","journal-title":"Lancet Oncol"},{"key":"2025033007272381800_CIT0043","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10900-013-9813-7","article-title":"Non-small cell lung cancer treatment receipt and survival among African-Americans and whites in a rural area","volume":"39","author":"Hua","year":"2014","journal-title":"J Community Health"},{"key":"2025033007272381800_CIT0044","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1097\/JTO.0b013e3182a406f6","article-title":"Stage-adjusted lung cancer survival does not differ between low-income Blacks and Whites","volume":"8","author":"Aldrich","year":"2013","journal-title":"J Thorac Oncol"},{"key":"2025033007272381800_CIT0045","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1158\/1055-9965.EPI-12-0560","article-title":"Lung cancer survival among black and white patients in an equal access health system","volume":"21","author":"Zheng","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025033007272381800_CIT0046","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1007\/s11606-015-3280-z","article-title":"Survival and racial differences of non-small cell lung cancer in the United States Military","volume":"30","author":"Brzezniak","year":"2015","journal-title":"J Gen Intern Med"},{"key":"2025033007272381800_CIT0047","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/1055-9965.EPI-05-0537","article-title":"Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer","volume":"15","author":"Mulligan","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025033007272381800_CIT0048","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1200\/JCO.2005.03.7077","article-title":"Lung cancer and race: equal treatment yields equal outcome among equal patients, but there is no equal treatment","volume":"24","author":"Brawley","year":"2006","journal-title":"J Clin Oncol"},{"key":"2025033007272381800_CIT0049","doi-asserted-by":"publisher","first-page":"e25665","DOI":"10.7759\/cureus.25665","article-title":"Comparison of pneumonitis rates and severity in patients with lung cancer treated by immunotherapy, radiotherapy, and immunoradiotherapy","volume":"14","author":"Aiad","year":"2022","journal-title":"Cureus"},{"key":"2025033007272381800_CIT0050","doi-asserted-by":"publisher","first-page":"e004670","DOI":"10.1136\/jitc-2022-004670","article-title":"Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study","volume":"10","author":"Tiu","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"2025033007272381800_CIT0051","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/1346-8138.15246","article-title":"Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan","volume":"47","author":"Otsuka","year":"2020","journal-title":"J Dermatol"},{"key":"2025033007272381800_CIT0052","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025033007272381800_CIT0053","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1111\/1759-7714.13149","article-title":"Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"10","author":"Komiya","year":"2019","journal-title":"Thorac Cancer"},{"key":"2025033007272381800_CIT0054","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"2025033007272381800_CIT0055","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3390\/biomedicines10040790","article-title":"Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)\u2014their incidence, management, multiorgan irAEs, and rechallenge","volume":"10","author":"Vaddepally","year":"2022","journal-title":"Biomedicines"},{"key":"2025033007272381800_CIT0056","doi-asserted-by":"publisher","first-page":"LMT18","DOI":"10.2217\/lmt-2019-0012","article-title":"Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions","volume":"8","author":"Metro","year":"2020","journal-title":"Lung Cancer Manag"},{"key":"2025033007272381800_CIT0057","doi-asserted-by":"publisher","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"2025033007272381800_CIT0058","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae279\/60875375\/oyae279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae279\/60875375\/oyae279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T20:15:00Z","timestamp":1743452100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae279\/7911768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae279","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,11,27]]},"article-number":"oyae279"}}